ACD/Labs Announces an Important Investment by Sanofi-Aventis for Production Facilities in Europe
News Apr 18, 2008
Advanced Chemistry Development, Inc., (ACD/Labs) recently sold a suite of NMR software to Sanofi-Aventis, for use by five of its Process Development teams in production facilities in France, Germany, and Hungary.
NMR analysis is used in drug manufacturing to help identify impurities and degradants during filing and scale-up production process, and can also be used in a quality assurance capacity to help monitor the composition of the finished product.
Sanofi-Aventis needed a solution that would allow the analytical groups at some of its European Process Development sites to support internal clients with NMR analysis. ACD/1D and 2D NMR Managers allow for off-instrument processing of analytical data and the ability to store results in a database searchable by structure as well as other parameters.
ACD/Labs’ NMR Predictors provide predictions of 1D (1H, 13C, 15N, 19F, and 31P) and 2D NMR spectra, to help in the rapid interpretation and identification of potential impurities and degradants.
“With the help of ACD/Labs software tools we expect to be able to provide results to our internal clients, more quickly and accurately than in the past,” said Philippe Cleon, Head of Structural Analysis in Process Development (Neuville, France). “We were impressed with the ease of use of the software as well as the accuracy of the results we were able to obtain with these tools.”
“Before and during the implementation process, Sanofi-Aventis will receive full technical support from our staff.” said Yves Lorrain, Director of Sales, Chemcad. Chemcad is the distributor of ACD/Labs products for parts of Western Europe, including France, Belgium, Spain, The Netherlands, Sweden, Norway, Finland, and Denmark.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE